Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2 —Biosimilar and Originator Etanercept in the Outpatient Setting

ConclusionsRegional variations in use of biosimilar etanercept can be seen although prices are coordinated nationally. This suggests that counties react differently to price differences and highlights the role of local policy and attitudes of stakeholders towards biosimilars and switching. It seems that some counties are hesitant to switch patients, as it is associated with an increased administrative workload that might not be compensated for by savings associated with a lower priced product.
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research